recent
year
biomed
commun
wit
rapid
scientif
technolog
evolut
follow
develop
refin
highthroughput
methodolog
concurr
consequenti
scientif
perspect
chang
reductionist
approach
meticul
analyz
fine
detail
singl
compon
biolog
holist
approach
broadmindedli
examin
global
interact
element
biolog
system
emerg
new
way
think
brought
scientif
revolut
genom
proteom
metabolom
omic
becom
predomin
tool
larg
amount
data
amass
analyz
appli
complex
question
biolog
previous
unsolv
enorm
transform
basic
scienc
research
ensu
plethora
promis
data
especi
realm
human
health
diseas
unfortun
follow
parallel
increas
clinic
applic
inform
contrari
number
new
potenti
drug
develop
steadili
decreas
suggest
exist
roadblock
prevent
translat
promis
research
medic
relev
therapeut
diagnost
applic
paper
review
noninclus
fashion
sever
recent
scientif
advanc
field
translat
research
specif
focu
relat
infecti
diseas
also
present
current
pictur
limit
challeng
exist
translat
research
well
way
propos
nation
institut
health
improv
state
field
translat
research
precis
defin
nation
institut
health
nih
process
appli
idea
insight
discoveri
gener
basic
scientif
inquiri
treatment
prevent
human
diseas
field
translat
research
becom
increasingli
popular
recent
year
undergon
numer
reiter
specif
mean
term
translat
research
redefin
sever
time
recent
evolut
nextgener
sequenc
techniqu
introduct
highthroughput
method
result
explos
cascad
research
applic
span
target
identif
diagnost
therapeut
technic
advanc
provid
impetu
radic
chang
way
research
conceiv
perform
result
enhanc
interact
broader
collabor
among
research
differ
expertis
requir
keep
rapidli
chang
state
scienc
order
multidisciplinari
approach
effect
better
way
collect
share
data
eg
biorepositori
must
identifi
addit
rapid
translat
inform
basic
scienc
use
clinic
applic
requir
remov
commun
barrier
financi
roadblock
current
prevent
basic
scienc
team
work
clinic
research
final
regulatori
chang
necessari
promot
faster
approv
new
molecular
entiti
nme
result
scientif
collabor
major
turn
point
valid
field
translat
research
came
creation
nih
clinic
translat
scienc
award
program
ctsa
support
nation
consortium
medic
research
institut
state
ctsa
largest
program
nation
center
research
resourc
ncrr
initi
establish
purpos
provid
resourc
tool
network
nih
research
nationwid
well
support
program
biomed
technolog
research
infrastructur
climat
rapid
scientif
develop
program
aim
provid
infrastructur
resourc
train
opportun
collabor
among
scientist
clinician
wide
varieti
disciplin
across
differ
institut
common
goal
program
facilit
transit
basic
scienc
discoveri
clinic
studi
commun
practic
health
care
decisionmak
although
program
ncrr
promot
higher
qualiti
train
improv
research
manag
enhanc
commun
particip
clinic
research
mani
roadblock
remain
translat
research
march
franci
collin
director
nih
announc
creation
new
nation
center
advanc
translat
scienc
ncat
assum
ctsa
dissolv
ncrr
redistribut
program
throughout
institut
center
aim
controversi
new
program
catalyz
progress
basic
scientif
discoveri
clinic
use
therapeut
diagnost
tool
identifi
bottleneck
translat
research
explor
innov
method
approach
remov
thu
creation
ncat
attempt
shift
current
paradigm
major
basic
scienc
discoveri
take
year
translat
clinic
relev
drug
long
time
period
cost
necessari
develop
approv
use
drug
also
neg
affect
pharmaceut
research
develop
particularli
area
infecti
diseas
drug
compani
curtail
ceas
antimicrobi
develop
despit
increas
antibiot
resist
bad
bug
similarli
despit
orphan
drug
act
pass
stimul
develop
drug
rare
diseas
pipelin
new
drug
target
diseas
interest
pharmaceut
compani
also
dri
ultim
creation
program
like
ncat
step
right
direct
chang
propos
organ
still
leav
sever
problem
unresolv
gener
new
seri
concern
review
noninclus
fashion
sever
exampl
basic
scienc
achiev
brought
forefront
translat
research
complet
review
translat
applic
recent
scientif
discoveri
transcend
purpos
articl
limit
discuss
field
infecti
diseas
overal
wish
draw
attent
gener
challeng
face
translat
research
defin
recent
realiz
achiev
futur
prospect
field
human
genom
project
initi
conceiv
consid
one
import
step
start
genom
era
definit
genom
character
hereditari
inform
organ
research
proteom
defin
structur
function
protein
encod
genom
organ
next
logic
step
genom
studi
biolog
system
sinc
protein
major
catalyst
intracellular
process
metabolom
use
systemat
analysi
complet
set
chemic
fingerprint
left
behind
certain
cellular
process
order
determin
key
aspect
function
regul
process
togeth
genom
proteom
metabolom
compris
three
major
system
biolog
approach
forefront
translat
research
fig
sinc
first
invent
late
dna
sequenc
one
influenti
innov
biolog
research
rapidli
evolv
techniqu
provid
feasibl
approach
multitud
problem
concern
biolog
includ
infecti
diseas
polymeras
chain
reaction
pcr
common
method
amplifi
nucleotid
sequenc
base
defin
primer
set
recogn
specif
region
dna
sampl
physician
routin
refer
data
pcr
sequenc
method
integr
part
standard
care
exampl
human
immunodefici
viru
hiv
medic
chosen
analyz
viru
genotyp
presenc
mutat
would
confer
resist
antiretrovir
drug
market
viral
load
viral
level
measur
pcr
use
help
predict
respons
therapi
similar
approach
also
use
viral
diseas
hepat
b
hbv
hepat
c
hcv
influenza
pcr
sequenc
techniqu
also
play
crucial
role
pathogen
discoveri
outbreak
investig
recent
year
import
field
highlight
grow
number
emerg
pathogen
rapid
spread
consequ
global
mobil
popul
climat
chang
improv
surveil
threat
bioterror
basic
research
clinic
microbiolog
laboratori
use
uniplex
multiplex
pcr
assay
rapid
identif
type
mani
bacteri
viral
pathogen
convent
uniplex
pcr
method
use
specif
target
set
primer
one
set
per
reaction
amplifi
conserv
genet
region
sampl
identifi
close
variant
known
pathogen
multiplex
pcr
assay
first
emerg
late
base
theori
amplifi
multipl
region
dna
singl
sampl
thu
produc
addit
inform
would
otherwis
requir
sever
time
amount
reagent
run
use
uniplex
pcr
although
multiplex
pcr
techniqu
signific
improv
compar
convent
pcr
approach
still
limit
abil
detect
new
pathogen
screen
larg
number
sequenc
effici
manner
introduct
microarray
technolog
mid
late
allow
develop
microarraybas
pathogen
detect
platform
highdens
panmicrobi
array
truli
made
rapid
screen
larg
number
pathogen
feasibl
applic
microarray
technolog
sampl
materi
suspect
contain
pathogen
genom
hybrid
array
gene
chip
hundr
thousand
miniatur
spot
contain
nucleic
acid
probe
specif
variou
pathogen
sequenc
microarraybas
pathogen
detect
platform
greenechip
virochip
use
oligonucleotid
probe
conserv
genet
region
within
taxonom
group
virus
length
probe
toler
sequenc
mismatch
therefor
allow
detect
unknown
microbi
target
furthermor
probe
continu
updat
new
virus
sequenc
ad
associ
databas
identifi
pathogen
clinic
specimen
nucleic
acid
randomli
amplifi
hybrid
chip
given
larg
number
probe
possibl
hybrid
success
result
analyz
help
comput
program
use
algorithm
statist
identifi
viru
hybrid
pattern
although
microarraybas
pathogen
detect
platform
instrument
detect
numer
pathogen
includ
novel
one
like
coronaviru
associ
sever
acut
respiratori
syndrom
sarscov
still
reli
prior
knowledg
relev
genom
sequenc
introduct
highthroughput
sequenc
revolution
abil
detect
novel
infecti
agent
whose
genom
sequenc
complet
unknown
present
extrem
low
number
highthroughput
sequenc
revolut
start
introduct
first
automat
sequenc
first
nextgener
sequenc
technolog
develop
year
later
took
nearli
year
technolog
improv
becam
commerci
avail
current
frequent
use
platform
type
includ
largescal
parallel
pyrosequenc
system
life
scienc
roch
illumina
solexa
sequencingbysynthesi
system
field
evolv
rapidli
new
platform
gener
regularli
develop
techniqu
allow
deep
sequenc
clinic
sampl
term
deep
refer
depth
coverag
averag
number
time
singl
nucleotid
sequenc
allow
high
level
accuraci
sequenc
determin
deep
sequenc
method
therefor
achiev
thousand
million
simultan
sequenc
read
per
run
allow
precis
determin
entir
genom
organ
ultradeep
sequenc
larg
enabl
platform
sequenc
system
provid
even
deeper
sequenc
coverag
allow
number
addit
applic
includ
amplicon
transcript
sequenc
detect
extrem
lowabund
genet
variat
sinc
pyrosequenc
techniqu
base
detect
light
produc
whenev
nucleotid
incorpor
reli
physic
separ
dna
base
platform
run
parallel
miniatur
reaction
volum
gener
detect
level
light
thu
drive
overal
cost
sequenc
nevertheless
shorter
read
necessit
deeper
sequenc
capac
nextgener
sequenc
creat
addit
challeng
sequenc
assembl
gene
annot
although
cost
sequenc
decreas
analysi
accumul
data
costli
timeconsum
comput
challeng
analysi
complic
fact
comput
system
discrimin
nucleic
acid
host
newlydiscov
infecti
agent
despit
challeng
sever
new
virus
identifi
use
deep
sequenc
system
addit
system
made
subsequ
step
pathogen
discoveri
includ
sequenc
entir
genom
facilit
develop
diagnost
techniqu
identif
potenti
therapeut
target
timeand
costeffect
beyond
pathogen
discoveri
sequencingbas
method
abil
discrimin
close
relat
strain
therefor
success
employ
studi
viral
variat
evolut
nextgener
sequenc
techniqu
also
provid
import
tool
enabl
epidemiologist
better
follow
persontoperson
transmiss
eventu
identifi
sourc
outbreak
case
recent
cholera
outbreak
haiti
sequenc
vibrio
cholera
genom
haitian
outbreak
compar
sequenc
previous
isol
strain
found
closelyrel
strain
isol
bangladesh
south
american
isol
similarli
highthroughput
sequenc
techniqu
allow
fast
sequenc
swine
flu
isol
determin
exact
origin
gene
segment
new
sequenc
techniqu
combin
advanc
molecular
medicin
also
drastic
improv
field
vaccin
discoveri
past
vaccin
constitut
crude
partiallypurifi
inactiv
viral
bacteri
prepar
often
carri
risk
seriou
allerg
reaction
autoimmun
diseas
due
impur
formul
furthermor
administr
vaccin
could
sometim
caus
diseas
illustr
vaccineinduc
paralyt
polio
although
problem
still
exist
presentday
vaccin
field
genom
pave
way
power
focus
techniqu
allow
better
understand
natur
pathogen
antigen
immun
system
tune
respond
optim
explos
sequenc
data
genom
era
genom
larg
number
medic
import
microb
decod
made
readili
avail
result
techniqu
revers
vaccinolog
emerg
allow
design
specificallytarget
vaccin
power
revers
vaccinolog
lie
abil
identifi
novel
vaccin
target
base
computerfacilit
predict
immunogen
preval
antigen
given
pathogen
without
ever
cultiv
specif
microorgan
potenti
suitabl
vaccin
target
identifi
gene
infecti
agent
encod
one
target
clone
express
vector
result
protein
express
vitro
use
immun
anim
model
antisera
deriv
correspond
antisera
test
abil
neutral
protect
origin
infecti
agent
use
inform
vaccin
design
elicit
specif
immun
respons
specifi
target
combin
ration
design
adjuv
whose
mechan
action
could
improv
vaccin
immunogen
one
exampl
success
use
process
recent
develop
vaccin
serogroup
b
neisseria
meningitid
array
potenti
vaccin
includ
target
group
b
streptococcu
pneumonia
speci
current
studi
one
techniqu
deriv
newli
sequenc
genom
viral
pathogen
revers
genet
made
possibl
gener
virus
entir
cotransfect
specif
engin
plasmid
dna
cell
cultur
techniqu
import
implic
vaccin
product
mean
specif
chang
revers
engin
sequenc
plasmid
dna
use
cotransfect
allow
extrem
fine
control
pathogen
immunogen
result
viru
revers
genet
use
success
develop
promis
candid
vaccin
target
influenza
virus
sever
group
explor
revers
genet
strategi
design
liveattenu
influenza
viru
vaccin
recent
phase
clinic
trial
demonstr
safeti
immunogen
revers
geneticsderiv
variant
influenza
viru
male
volunt
revers
genet
also
use
pathogenet
studi
case
insert
mutagenesi
delet
specif
sequenc
plasmid
transfect
clarifi
effect
modif
viral
infect
help
elucid
function
modifi
protein
context
viral
lifecycl
final
abil
exert
exquisit
control
viral
sequenc
would
permit
identif
specif
sequenc
alter
promot
viral
attenu
inform
use
design
gener
new
vaccin
addit
applic
risen
genom
revolut
includ
use
genet
alter
viral
vector
altern
approach
vaccin
conduit
deliv
antibodi
passiv
immunotherapi
use
sequenc
data
design
specif
inhibitor
antivir
approach
current
studi
also
like
come
forefront
near
futur
genom
revolut
significantli
improv
way
detect
prevent
treat
infecti
diseas
advanc
field
continu
decreas
time
necessari
identifi
newli
emerg
human
pathogen
produc
new
vaccin
clinic
relev
infect
proteom
predominantli
mass
spectrometri
ms
base
techniqu
deal
largescal
evalu
cellular
function
protein
level
ms
analysi
accomplish
ioniz
sampl
molecular
compon
eg
electron
beam
laser
etc
pass
electromagnet
field
separ
ratio
molecular
mass
charg
mz
proteom
analysi
oppos
msbase
techniqu
seek
specif
elucid
entir
complement
protein
protein
modif
andor
interact
specimen
given
time
sinc
protein
major
effector
cellular
pathway
proteom
provid
way
interpret
inform
encod
within
genom
organ
sinc
term
proteom
first
coin
field
expand
tremend
larg
due
develop
ioniz
analyt
methodolog
allow
effici
separ
detect
almost
protein
compon
within
sampl
interest
unlik
genom
method
instrument
current
exist
capabl
identifi
quantifi
compon
complex
protein
sampl
singl
step
instead
combin
step
vari
methodolog
instrument
use
proteom
platform
character
two
key
step
protein
separ
mostli
obtain
either
electrophoret
chromatograph
method
protein
analysi
use
primarili
msbase
techniqu
twodimension
electrophoresi
develop
method
allow
protein
contain
within
complex
biolog
mixtur
separ
isoelectr
point
molecular
weight
visual
stain
today
proteom
approach
remain
gold
standard
separ
complex
protein
mixtur
despit
sever
limit
includ
detect
rel
abund
protein
complex
mix
poor
separ
insolubl
andor
hydrophob
protein
protein
comigr
laborintens
natur
identifi
multipl
protein
spot
result
gel
address
problem
comigr
modif
known
twodimension
differenti
ingel
electrophoresi
dige
develop
techniqu
multipl
protein
sampl
separ
label
fluoresc
dye
mix
togeth
resolv
singl
gel
elimin
need
crossgel
comparison
increas
overal
statist
power
inclus
greater
number
sampl
develop
dige
repres
improv
need
increas
sensit
detect
effici
separ
protein
within
complex
mixtur
remain
drive
forc
behind
develop
gelfre
technolog
gelfre
proteom
approach
made
possibl
coupl
physic
separ
capabl
chromatograph
techniqu
mass
analysi
capabl
tandem
mass
spectrometri
msm
chromatographi
techniqu
involv
move
compon
separ
mobil
phase
across
immobil
support
stationari
phase
migrat
rate
solut
ie
protein
vari
depend
chemic
properti
liquid
chromatographi
lc
mobil
phase
liquid
one
widelyus
protein
separ
techniqu
proteom
use
smaller
particl
less
monolith
column
use
porou
channel
rather
bead
extrem
high
pressur
psi
high
ultrahigh
perform
lc
hplc
uhplc
drastic
improv
effici
resolut
protein
separ
hplc
complex
protein
mixtur
digest
trypsin
peptid
compon
move
liquid
mobil
phase
high
pressur
across
stationari
phase
allow
separ
base
polar
next
sort
peptid
compon
analyz
msm
first
mass
spectromet
program
detect
peptid
rang
predetermin
mass
order
distinguish
target
interest
vast
array
protein
typic
present
complex
biolog
fluid
result
data
use
pinpoint
ion
interest
fragment
measur
record
second
mass
spectromet
data
final
comput
algorithm
use
aid
research
identifi
individu
protein
combin
data
exampl
sequest
algorithm
develop
use
fragment
spectra
peptid
infer
amino
acid
sequenc
match
translat
genom
sequenc
approach
identif
rate
greater
protein
per
run
newest
iter
softwar
macrosequest
featur
enhanc
capabl
eg
posttransl
modif
scan
dramat
improv
process
speed
compar
origin
version
combin
hplc
msm
known
shotgun
proteom
proven
fast
highli
sensit
approach
especi
scale
micro
nano
flow
rate
shotgun
proteom
allow
identif
thousand
individu
protein
within
given
sampl
essenti
prior
knowledg
compon
peptid
also
greatli
facilit
analysi
entir
proteom
although
shotgun
proteom
repres
signific
technolog
advanc
analysi
complex
biolog
mixtur
concentr
individu
protein
within
sampl
low
enough
requir
level
sensit
beyond
even
standard
hplc
condit
achiev
reduc
flow
rate
column
diamet
level
sensit
obtain
adapt
system
special
requir
nanolit
flow
rate
nlmin
anoth
shortcom
shotgun
proteom
inabl
onedimension
hplc
provid
suffici
separ
power
manag
vast
complex
protein
inher
biolog
specimen
address
issu
multidimension
separ
approach
multidimension
protein
identif
technolog
mudpit
combin
strong
cation
exchang
chromatographi
hplc
develop
even
improv
advanc
shotgun
proteom
platform
still
identifi
approxim
protein
predict
microbi
genom
less
proteom
higher
complex
furthermor
actual
proteom
size
may
smaller
larger
predict
genom
due
absenc
transcript
protein
altern
splice
andor
posttransl
modif
other
therefor
shotgun
proteom
enabl
identif
rel
abund
larg
number
protein
sampl
optim
absolut
protein
quantit
addit
identifi
protein
within
complex
biolog
mixtur
need
quantit
compon
provid
inform
regard
dynam
within
context
biolog
system
ad
focu
led
emerg
deriv
field
known
quantit
proteom
protein
quantit
rel
absolut
rel
protein
abund
may
estim
sever
method
includ
measur
total
number
repeat
observ
msm
spectra
peptid
protein
spectral
count
calcul
percentag
possibl
peptid
per
protein
observ
peptid
count
directli
compar
extract
ion
chromatogram
xic
align
use
mass
elut
time
one
sampl
anoth
sampl
labelfre
techniqu
greatli
facilit
develop
new
commerci
avail
softwar
program
mzmine
mapquant
superhirn
altern
protein
quantif
may
accomplish
combin
shotgun
proteom
techniqu
stabl
isotop
label
use
approach
sampl
differenti
label
stabl
isotop
heavi
vs
light
pool
analyz
togeth
peptid
common
sampl
label
differ
isotop
behav
analysi
detect
peak
pair
compar
size
peak
rel
abund
peptid
sampl
compar
method
absolut
quantit
protein
abund
desir
mani
case
eg
determin
copi
per
cell
one
technolog
address
need
commonplac
clinic
set
call
multipl
reaction
monitor
also
known
select
reaction
monitor
mrmsrm
techniqu
exploit
uniqu
capabl
tripl
quadrupol
qqq
ms
analyz
precursor
fragment
ion
pair
qqq
ms
use
three
set
four
circular
metal
rod
quadrupol
run
parallel
first
quadrupol
act
specif
select
peptid
ion
predefin
mz
valu
peptid
fragment
second
quadrupol
serv
collis
cell
third
quadrupol
set
either
scan
entir
mz
rang
order
provid
inform
structur
origin
ion
filter
fragment
specif
mz
valu
may
indic
particular
characterist
eg
function
group
mrmsrm
provid
target
inform
sensit
attomol
level
multipl
peptid
across
wide
concentr
scale
within
singl
sampl
sensit
mrmsrm
techniqu
also
improv
enrich
target
complex
background
use
antibodymedi
approach
stabl
isotyp
captur
antipeptid
antibodi
siscapa
immunomatrixassist
laser
desorptionion
imaldi
rel
protein
quantit
absolut
protein
quantit
possess
arsen
comput
program
design
assist
analysi
mrmsrm
data
includ
skylin
mrm
srm
builder
mrmpilot
ab
peptid
optim
dynam
mrm
softwar
agil
marimba
mrmaid
mrmer
date
analyt
platform
given
rise
four
major
proteom
applic
global
protein
profil
analysi
protein
within
given
biolog
unit
sampl
analysi
protein
modif
phosphoryl
ubiquitin
nitrosyl
etc
analysi
proteinprotein
interact
analysi
proteingen
interact
regard
studi
infecti
diseas
global
protein
profil
use
shotgun
proteom
recent
use
identifi
quantit
protein
express
malaria
parasit
plasmodium
falciparum
accord
stage
life
cycl
host
compart
studi
result
candid
protein
possibl
stagespecif
drug
vaccin
target
addit
gener
inform
larg
set
orphan
protein
protein
could
map
genom
found
set
previous
known
protein
protein
interact
protein
express
stage
parasit
life
cycl
analysi
protein
modif
use
identifi
phosphoprotein
signal
pathway
alter
rift
valley
fever
virusinfect
airway
epitheli
cell
uncov
potenti
target
reactiv
nitrogen
intermedi
mycobacterium
tuberculosi
thu
inform
potenti
target
novel
antivir
antimycobacteri
compound
final
analys
proteinprotein
proteingen
interact
use
studi
relationship
epsteinbarr
viru
ebv
infect
nasopharyng
carcinoma
well
alter
host
cellular
process
associ
viral
replic
recent
studi
also
aim
establish
context
type
interact
occur
combin
proteomicbas
techniqu
either
cryoelectron
tomographi
membran
shave
proteinas
k
digest
look
specif
cellular
local
approach
success
use
map
spatial
proteom
leptospira
interrogan
membran
proteom
aureu
studi
may
ultim
lead
improv
understand
microbi
pathogenesi
provid
import
clue
identif
novel
biomark
antivir
sinc
protein
carri
mani
function
biolog
activ
proteom
analysi
organ
provid
layer
detail
beyond
genom
although
still
emerg
technolog
proteom
alreadi
profound
impact
clinic
biolog
research
inform
pathogenesi
diseas
facilit
biomark
discoveri
aid
identif
potenti
drug
target
new
develop
ms
platform
msbase
tissu
imag
techniqu
combin
proteomicgenom
approach
like
extend
impact
proteom
drug
design
test
well
pathogen
identif
discoveri
continu
advanc
understand
complex
biolog
process
newest
field
system
biolog
metabolom
defin
comprehens
simultan
systemat
determin
metabolit
level
whole
organ
chang
time
consequ
stimuli
diet
lifestyl
environ
genet
effect
pharmaceut
intervent
benefici
advers
concis
definit
metabolom
might
global
profil
small
molecul
metabolit
contain
within
sampl
interest
given
time
metabolit
intermedi
product
cellular
process
typic
fall
one
four
categori
amino
acid
nucleotid
lipid
sugar
moreov
metabolit
repres
level
pharmaceut
exert
effect
therefor
studi
product
consumpt
chemic
fingerprint
one
gain
insight
dynam
function
biolog
system
analyt
techniqu
employ
metabolom
studi
larg
similar
use
proteom
studi
base
primarili
either
nuclear
magnet
reson
nmr
spectroscopi
ms
typic
workflow
involv
mechan
extract
coupl
rapid
cool
step
halt
metabol
nativ
state
follow
detect
either
via
nmr
ms
data
analysi
msbase
metabolom
requir
addit
separ
compon
either
ga
gc
lc
enhanc
molecular
identif
molecul
within
sampl
interest
lcmsbase
metabolom
gener
three
piec
data
chromatograph
retent
time
inform
chemic
structur
mz
ratio
inform
molecular
mass
abund
retent
time
mz
ratio
may
queri
librari
known
standard
determin
ident
metabolit
nmrbase
metabolom
analysi
contrast
provid
nondestruct
way
look
broadli
chang
metabolit
level
either
vitro
vivo
moreov
provid
detail
structur
inform
ms
sinc
ms
analysi
provid
better
resolut
sensit
remain
predomin
methodolog
analyz
metabol
data
metabolom
analys
result
complex
multivari
dataset
requir
visual
softwar
spectral
analysi
well
bioinformat
statist
methodolog
interpret
metabolom
analysi
data
set
produc
nmr
ms
yield
two
major
applic
steadi
state
metabolit
profil
label
flux
analysi
steadi
state
metabolit
profil
may
global
profil
small
molecul
metabolit
within
sampl
target
analysi
prespecifi
metabolit
interest
use
discov
new
biomark
inform
dysregul
pathway
associ
diseas
gener
inform
cellular
function
label
flux
analysi
radiolabel
isotop
use
analyz
chang
amount
given
metabolit
use
produc
particular
metabol
pathway
approach
yield
detail
inform
dynam
natur
biolog
pathway
use
better
identifi
potenti
therapeut
target
recent
henderson
et
al
util
steadi
state
lcmsbase
metabolom
approach
identifi
bacteri
strain
associ
urinari
tract
infect
uti
differ
colon
gastrointestin
gi
tract
result
indic
urinari
e
coli
strain
preferenti
express
two
small
molecul
yersiniabactin
salmochelin
known
import
ironscaveng
support
bacteri
surviv
growth
find
suggest
new
antibiot
direct
yersiniabactinor
salmochelinproduc
e
coli
strain
may
improv
target
strategi
prevent
recurr
uti
anoth
exampl
munger
et
al
use
chang
metabol
flux
uninfect
human
cytomegalovirusinfect
cell
identifi
pathway
upregul
viral
infect
thu
provid
import
inform
regard
potenti
target
novel
antivir
aim
block
viral
replic
lipidom
glycom
two
grow
field
relat
metabolom
merit
special
mention
lipidom
largescal
studi
network
pathway
employ
cellular
lipid
employ
larg
tool
use
metabolom
specif
modif
accommod
uniqu
characterist
lipid
lipid
key
function
signal
pathway
energi
storag
structur
integr
cell
membran
also
play
import
role
hostpathogen
interact
immunomodul
glycom
comprehens
studi
sugar
organ
sinc
cellular
sugar
simpl
sugar
glycoprotein
glycolipid
common
experiment
approach
analysi
instead
glycom
studi
use
combin
techniqu
found
metabolom
proteom
lipidom
glycoconjug
particip
varieti
biolog
process
associ
cell
adhes
migrat
bacteri
viral
recognit
signal
pathway
innat
immun
therefor
studi
chang
lipid
sugar
compon
biolog
system
provid
power
clue
diseaserel
mechan
novel
therapeut
target
inde
approach
shown
particular
promis
studi
infecti
diseas
lipidom
use
uncov
mechan
involv
enhanc
drug
suscept
candida
albican
gain
insight
regard
intracellular
process
lipid
composit
hiv
cmv
hcv
identifi
lipidom
modif
occur
host
result
bacteri
viral
infect
util
glycom
also
recent
demonstr
character
specif
interact
viral
protein
variou
form
sialic
acid
detail
analysi
lipopolysaccharid
coxiella
burnetii
may
contribut
pathogenesi
discoveri
glycan
coat
virion
match
cell
immunomodulatori
microvesicl
deriv
suggest
mechan
viru
evad
antivir
immun
respons
aforement
exampl
demonstr
potenti
metabolom
tool
enhanc
develop
novel
diagnost
therapeut
like
proteom
metabolom
alreadi
use
vehicl
investig
diseas
pathogenesi
potenti
biomark
therapeut
target
move
forward
improv
autom
metabolit
identif
expand
exponenti
potenti
use
metabolomicsbas
approach
addit
integr
metabolom
data
global
profil
techniqu
genom
proteom
allow
deeper
understand
biolog
pathway
possibl
date
unparallel
possibl
clinic
applic
advent
genom
proteom
metabolom
came
explos
omic
scienc
convent
aros
part
suffix
ome
omic
succinctli
describ
holist
way
look
relationship
exist
within
rel
complex
scientif
domain
howev
trend
also
reflect
grow
involv
bioinformat
internet
way
integr
complex
biolog
data
concurr
signific
advanc
omic
scienc
allow
better
understand
molecular
cellular
process
occur
within
human
research
also
began
appreci
number
complex
organ
resid
human
bodi
follow
public
human
genom
sequenc
scientist
began
call
second
human
genom
project
would
catalog
complet
inventori
microbi
genom
major
site
colon
human
bodi
sinc
microbiota
believ
play
fundament
import
role
human
health
diseas
microbi
inventori
combin
comprehens
analysi
host
gene
express
would
provid
insight
mechan
interact
landmark
studi
publish
eckburg
et
al
use
rrna
sequenc
techniqu
character
endogen
gastrointestin
microbi
flora
three
individu
author
conclud
bacteri
commun
vari
tremend
one
individu
next
studi
came
indic
largerscal
investig
human
microbi
ecosystem
warrant
thu
nih
initi
fiveyear
project
call
human
microbiom
project
hmp
hmp
use
variou
omic
approach
order
character
complex
microbi
commun
determin
exist
core
microbiom
variou
colon
site
human
bodi
examin
relationship
chang
microbiom
human
health
fig
date
hmp
determin
substanti
alter
human
microbiom
import
varieti
diseas
state
includ
psoriasi
sexual
transmit
infect
male
urogenit
tract
crohn
diseas
gastroesophag
reflux
diseas
other
also
grow
interest
regard
effect
gut
microbiom
develop
immun
system
recent
studi
show
mice
treat
antibiot
deplet
specif
gut
bacteri
popul
would
impair
virusspecif
cellmedi
humor
respons
lung
follow
infect
influenza
viru
data
requir
confirm
indepth
studi
address
mechan
howev
rais
seri
new
question
role
bacteri
microbiota
human
health
hmp
made
major
advanc
understand
human
microbiom
also
significantli
contribut
grow
field
metagenom
develop
broadlyapplic
techniqu
analyz
massiv
amount
sequenc
data
exampl
langmead
et
al
design
cloudcomput
softwar
tool
call
crossbow
rapidli
analyz
larg
dna
sequenc
dataset
coverag
human
genom
three
hour
order
perform
align
detect
singl
nucleotid
polymorph
snp
without
sacrif
accuraci
anoth
group
develop
robust
softwar
program
call
qiim
pronounc
chime
stand
quantit
insight
microbi
ecolog
analyz
pyrosequenc
data
thousand
heterogen
experiment
dataset
order
rapidli
acquir
inform
variou
microbi
commun
although
hmp
fund
least
one
project
aim
character
relationship
virus
human
ill
primari
focu
project
current
bacteri
popul
therefor
although
welldefin
hmp
least
two
infecti
diseaserel
ome
emerg
parallel
human
virom
human
mycobiom
compris
myriad
virus
fungi
respect
inhabit
human
biospher
play
role
health
diseas
fig
anderson
et
al
propos
system
global
screen
virus
larg
human
popul
although
global
screen
limit
virus
persist
chronic
human
bodi
case
commens
bacteria
popul
includ
hmp
system
could
lay
groundwork
rapid
detect
outbreak
systemat
discoveri
novel
human
virus
well
provid
better
clue
etiolog
human
diseas
exampl
one
studi
investig
human
virom
uncov
differ
metabol
state
dna
virom
respiratori
tract
cystic
fibrosi
cf
compar
noncf
patient
anoth
group
demonstr
bacteriophag
popul
becam
similar
gut
individu
diet
similar
fat
content
thu
rais
possibl
viru
popul
could
engin
combat
obes
contrast
studi
regard
human
mycobiom
seem
still
infanc
first
studi
describ
baselin
mycobiom
human
recent
publish
studi
author
use
multitag
pyrosequenc
character
fungi
present
oral
caviti
healthi
individu
abl
identifi
differ
similar
white
asian
popul
light
major
advanc
genotyp
character
bacteri
viral
mycot
pathogen
associ
human
clear
addit
holist
approach
requir
fulli
understand
phenotyp
interact
may
affect
human
health
diseas
thu
emerg
field
infectom
aim
effici
accur
integr
studi
structur
function
genom
proteom
microbi
infect
fig
wherea
microbiom
virom
mycobiom
identifi
comprehens
inventori
microb
inhabit
human
bodi
infectom
examin
distinct
signatur
microb
vari
depend
host
microbi
gene
express
tissu
type
infect
dynam
characterist
host
pathogen
network
infectom
human
diseasom
fig
link
certain
diseas
togeth
base
common
gene
express
profil
possibl
identifi
link
microbi
infect
etiolog
human
diseas
could
inform
design
better
vaccin
therapeut
need
manag
rapidli
accumul
number
sequenc
massiv
amount
data
highthroughput
platform
requir
develop
sophist
comput
program
abl
analyz
integr
data
thu
system
biolog
develop
new
field
aim
understand
complex
pathogenhost
interact
use
comput
integr
highthroughput
experiment
data
model
molecular
network
via
bioinformat
intrins
approach
idea
biolog
system
display
emerg
properti
complex
pattern
aris
multipl
rel
simpl
interact
therefor
major
object
system
biolog
approach
regard
infecti
diseas
abl
make
predict
dynam
behavior
biochem
network
involv
infect
pathogen
thu
smallscal
studi
look
one
side
interact
system
biolog
give
global
perspect
event
umbrella
system
biolog
four
main
approach
relev
studi
infecti
diseas
system
biolog
viral
bacteri
pathogen
system
immunolog
system
vaccinolog
highthroughput
drug
discoveri
common
approach
goal
integr
highthroughput
multiom
data
construct
predict
model
network
dynam
interact
pathogen
host
order
quickli
identifi
prevent
therapeut
target
clinic
develop
recogn
import
system
biolog
understand
integr
practic
applic
result
highthroughput
screen
field
infecti
diseas
hostpathogen
interact
nation
institut
allergi
infecti
diseas
niaid
creat
system
biolog
infecti
diseas
research
program
research
activ
program
initi
separ
four
center
tuberculosi
tb
system
biolog
center
system
virolog
center
center
system
influenza
center
system
biolog
enteropathogen
center
use
comput
experiment
methodolog
comprehens
analyz
model
hostpathogen
interact
order
determin
extent
molecular
cellular
network
induc
alter
cours
infect
overarch
goal
program
gener
develop
reagent
protocol
statist
model
rapidli
made
avail
scientif
commun
order
promot
swift
advanc
scientif
research
translat
clinic
practic
purpos
tb
system
biolog
center
model
molecular
pathway
tuberculosi
condit
relev
tb
pathogenesi
use
combin
experiment
comput
techniqu
exampl
chromatin
immunoprecipit
follow
nextgener
dna
sequenc
analysi
chipseq
power
techniqu
use
precis
map
global
dna
bind
site
protein
interest
regul
gene
express
within
context
pathogenesi
fulli
understood
combin
techniqu
varieti
omic
data
transcriptom
proteom
glycom
metabolom
lipidom
etc
vitro
vivo
growth
tuberculosi
tb
system
biolog
center
aim
measur
baselin
metabol
topolog
state
gene
regulatori
network
tuberculosi
delin
global
alter
occur
pathogen
host
infect
host
macrophag
integr
profil
data
develop
predict
comput
model
bacteri
regulatori
metabol
network
use
model
predict
made
regard
state
network
infect
tuberculosi
lead
addit
hypothesisdriven
research
system
virolog
center
center
system
influenza
similarli
aim
use
system
biolog
comprehens
analyz
model
alter
occur
molecular
cellular
event
cours
viru
infect
provid
deeper
understand
process
lead
initi
progress
infecti
diseas
system
virolog
center
focu
creat
unifi
view
mechan
pathogenesi
highli
pathogen
respiratori
virus
includ
pandem
influenza
viru
avian
influenza
viru
sarscov
contrast
center
system
influenza
specif
focu
defin
host
innat
immun
respons
infect
influenza
viru
strain
vari
pathogen
well
character
regulatori
network
associ
concurr
secondari
infect
like
aureu
date
sever
specif
achiev
come
center
use
techniqu
call
weight
gene
correl
network
analysi
wgcna
relationship
gene
coexpress
weight
base
strength
capac
transcript
respons
human
bronchial
epitheli
cell
infect
highli
pathogen
avian
influenza
viru
profil
compar
cell
infect
less
virul
strain
order
identifi
potenti
novel
mediat
pathogenesi
anoth
group
perform
comprehens
proteom
analysi
use
lcmsm
identifi
larg
number
human
host
protein
associ
polymeras
complex
influenza
viru
addit
previous
publish
interact
method
identifi
novel
interact
viral
polymeras
host
mitochondri
apoptosisinduc
innat
antivir
rna
polymeras
accessori
protein
could
provid
new
insight
mechan
viral
polymeras
may
contribut
host
cell
pathogen
addit
center
use
nextgener
sequenc
analysi
host
transcriptom
respons
influenza
viru
sarscov
infect
investig
beyond
proteom
character
role
nonproteincod
rna
regul
host
innat
immun
respons
final
center
system
biolog
enteropathogen
use
comput
experiment
omic
methodolog
analyz
model
interact
occur
host
macrophag
salmonella
enterica
yersinia
pesti
bacteri
speci
order
shed
light
mechan
behind
outcom
infect
either
bacteri
replic
host
cell
death
contain
pathogen
research
affili
center
develop
use
constraintbas
reconstruct
analysi
cobra
method
simul
analyz
predict
way
metabol
process
behav
variou
microorgan
anoth
studi
novel
virul
factor
enterica
includ
new
class
transloc
effector
discov
character
samplematch
multom
measur
variou
mutant
strain
comput
approach
support
vector
machinebas
identif
evalu
virul
effector
siev
also
use
facilit
identif
secret
bacteri
effector
protein
genom
sequenc
inform
order
fulli
understand
mechan
drug
vaccin
combat
diseas
one
must
also
grasp
way
human
immun
system
respond
infectom
unfortun
scienc
analyz
fine
detail
immun
higher
higher
resolut
actual
decreas
abil
predict
system
behav
whole
context
infect
end
research
begun
take
system
biolog
approach
immunolog
one
exampl
effort
meet
challeng
amass
highqual
quantit
data
use
avail
technic
advanc
omic
scienc
provid
organ
analyz
data
way
meaning
studi
immunolog
develop
niaid
program
system
immunolog
infecti
diseas
model
becam
laboratori
system
biolog
lsb
rather
collect
independ
laboratori
lsb
integr
group
scientist
staff
play
major
role
foster
growth
system
biolog
effort
within
unit
state
abroad
forefront
field
rapidli
increas
collect
system
biolog
techniqu
appli
uniqu
set
problem
encount
intersect
human
immun
system
infecti
diseas
exampl
comput
simul
molecular
dynam
associ
dissoci
posttransl
modif
larg
peptid
fold
process
use
frequent
field
system
immunolog
character
receptorligand
interact
occur
host
pathogen
one
studi
use
techniqu
model
system
ebv
demonstr
cell
receptor
tcr
structur
appear
frequent
other
due
certain
pattern
recognit
receptor
prr
like
trait
occur
within
cell
repertoir
anoth
group
use
constant
ph
molecular
dynam
simul
investig
mechan
behind
ligandbind
activ
innat
immun
system
prr
recogn
phsensit
microbi
protein
order
better
understand
type
interact
play
role
immunesurveil
clearanc
apoptot
cell
addit
simul
model
dynam
molecularlevel
interact
sever
program
emerg
combin
techniqu
system
biolog
inform
provid
datadriven
predict
method
due
advanc
predict
capac
system
biolog
research
newest
version
comput
simul
softwar
cimmsim
better
abl
model
immun
respons
silico
creator
cimmsim
recent
demonstr
varieti
new
applic
access
improv
program
includ
model
primari
secondari
respons
primeboost
immun
way
immunodomin
peptid
lead
affin
matur
relationship
divers
mhc
time
aid
hivinfect
patient
anoth
simul
framework
made
way
public
domain
multiscal
system
immunolog
msi
platform
aim
model
earli
immun
respons
vaccin
natur
infect
incorpor
realist
biophys
intracellular
dynam
grow
field
system
vaccinolog
combin
modern
analyt
tool
system
biolog
data
human
immunolog
respons
pattern
vaccin
order
uncov
molecular
signatur
vaccin
efficaci
guid
design
evalu
new
vaccin
recent
system
vaccinolog
use
studi
immun
respons
vaccin
yellow
fever
viru
yfv
although
yfv
vaccin
use
human
sinc
littl
known
vaccin
protect
infect
advent
system
vaccinolog
scientist
abl
comprehens
examin
initi
molecular
signatur
individu
vaccin
yfv
elucid
mechan
behind
vaccin
efficaci
also
establish
predict
correl
later
develop
protect
respons
system
vaccinolog
also
util
establish
predict
correl
protect
antibodi
respons
follow
administr
trival
inactiv
influenza
viru
vaccin
similar
approach
appli
studi
immun
respons
brucella
melitensi
fungal
infect
ideal
develop
model
defin
inher
infectionmedi
perturb
genet
regulatori
network
host
enabl
predict
host
respond
vaccin
base
model
design
vaccin
induc
optim
immun
respons
without
toxic
effect
thu
improv
vaccin
safeti
profil
correl
vaccineinduc
protect
immun
respons
infect
well
defin
help
system
vaccinolog
new
methodolog
must
identifi
appli
inform
design
develop
new
vaccin
likeli
common
exist
among
mani
differ
vaccin
regard
correl
success
immun
respons
drive
faster
accur
way
screen
vaccin
candid
effect
exampl
pulendran
et
al
predict
develop
vaccin
chip
microarray
similar
mammaprint
prognost
chip
develop
breast
cancer
abl
predict
immunogen
vaccin
although
specif
technolog
may
far
still
exist
theori
sever
system
biolog
approach
current
use
aid
antigen
discoveri
vaccin
develop
phage
display
one
techniqu
enabl
screen
identif
uniqu
molecul
highli
specif
affin
target
interest
approach
work
introduc
foreign
sequenc
appropri
site
within
bacteriophag
coat
protein
gene
result
display
protein
phage
surfac
random
sequenc
insert
possibl
obtain
librari
contain
larg
number
distinct
protein
display
differ
phage
immobil
dna
protein
target
solid
surfac
librari
pan
phage
recogn
target
wash
phage
bind
target
wash
away
specif
phage
elut
use
produc
phage
thu
enrich
popul
relev
bind
phage
enabl
isol
specif
protein
interest
use
subsequ
applic
phage
display
power
techniqu
due
mani
applic
vaccin
drug
develop
one
applic
phage
display
technolog
identif
epitop
repertoir
antibodi
postvaccin
human
sera
end
khurana
et
al
use
influenza
viru
whole
genomefrag
phage
display
librari
evalu
qualiti
antibodi
respons
human
follow
immun
novel
viruslik
particl
vaccin
approach
also
enabl
author
determin
appropri
dosag
vaccin
induc
desir
antibodi
repertoir
help
evalu
use
incorpor
adjuv
vaccin
war
infecti
diseas
abil
develop
nontox
fastact
therapeut
prophylact
drug
import
abl
design
safe
efficaci
vaccin
besid
use
evalu
efficaci
vaccineinduc
immun
respons
phage
display
also
use
identifi
synthes
monoclon
antibodi
mab
use
therapeut
purpos
varieti
infect
addit
benefit
antibodi
identif
phage
display
sinc
phage
librari
gener
set
sequenc
possibl
display
human
antibodi
fragment
thu
avoid
side
effect
inher
human
chimer
antibodi
approach
produc
sever
mab
potenti
therapeut
applic
agent
infecti
diseas
includ
influenza
viru
clostridium
difficil
hiv
viral
hepat
rabi
pseudomona
aeruginosa
methicillinresist
aureu
bacillu
anthraci
mab
target
protect
antigen
b
anthraci
raxibacumab
far
one
met
criteria
approv
fda
grow
emerg
antibioticresist
bacteri
strain
everpres
public
health
threat
pandem
viral
infect
increas
pressur
scientif
commun
discov
test
produc
novel
antimicrobi
drug
highthroughput
method
synthesi
screen
increas
number
target
result
omic
revolut
significantli
advanc
search
new
therapeut
combinatori
chemistri
divers
orient
synthesi
do
two
import
new
methodolog
drug
discoveri
drastic
reduc
time
cost
associ
produc
effect
market
competit
new
drug
power
techniqu
come
abil
synthes
extrem
larg
librari
highqual
compound
complex
molecular
divers
increas
likelihood
interact
biolog
macromolecul
select
manner
high
affin
phage
display
librari
also
wide
use
screen
novel
drug
candid
base
specif
proteinprotein
interact
although
frequent
cheaper
chemic
synthesi
methodolog
still
sever
limit
regard
stop
codon
placement
within
display
sequenc
ineffici
transform
method
peptid
length
restrict
use
natur
occur
amino
acid
nevertheless
sever
proofofprincipl
studi
recent
perform
order
overcom
limit
includ
one
studi
demonstr
incorpor
genet
encod
unusu
amino
acid
may
feasibl
follow
synthesi
potenti
molecular
target
highthroughput
screen
necessari
test
compound
larg
natur
synthet
librari
vitro
silico
assay
identifi
highli
specif
biolog
activ
defin
target
interest
although
mani
differ
assay
use
highthroughput
screen
gener
principl
specif
molecular
target
pathway
interest
systemat
combin
possibl
drug
compound
verifi
manual
autom
platform
posit
result
hit
result
hit
would
select
base
strongli
interact
target
addit
confirmatori
experi
would
perform
character
interact
incorpor
autom
comput
method
nanotechnolog
allow
enorm
increas
effici
develop
combinatori
librari
highthroughput
screen
potenti
use
drug
illustr
rapidli
acceler
success
method
recent
paper
report
achiev
ultrahighthroughput
screen
speed
million
individu
enzym
reaction
hour
use
small
reagent
volum
repres
increas
speed
millionfold
reduct
cost
compar
standard
highthroughput
techniqu
neg
consequ
massiv
amount
data
gener
highand
ultrahighthroughput
technolog
bottleneck
occur
level
drug
develop
optim
past
decad
express
protein
describ
potenti
drug
target
yet
exploit
commerci
therefor
despit
optim
engend
highthroughput
screen
advanc
drug
discoveri
valid
numer
obstacl
remain
translat
vast
amount
data
clinic
applic
human
genom
project
brought
conceptu
shift
focu
medicin
treatment
predict
diseas
prevent
side
effect
result
principl
manifest
diseas
influenc
interact
host
infecti
agent
character
host
genet
correl
diseas
would
help
predict
individu
suscept
specif
infectionrel
patholog
recent
technolog
advanc
sequenc
comput
biolog
facilit
identif
host
factor
predispos
affect
respons
diseas
therefor
therapi
tailor
accord
genet
makeup
host
characterist
microb
respons
diseas
franci
collin
suggest
genet
could
integr
medicin
either
use
classic
old
genet
develop
genet
test
monogen
diseas
prenat
diagnost
use
new
genet
predict
patient
respons
implement
person
medicin
clinic
applic
person
medicin
principl
may
seem
almost
visionari
year
ago
approach
use
routin
treatment
diseas
exampl
genom
data
use
make
accur
predict
suscept
patient
diseas
hesh
respond
treatment
specif
applic
person
medicin
common
diseas
cancer
caus
solid
tumor
hematolog
malign
patient
genet
test
determin
likelihood
respond
therapi
seriou
advers
reaction
variou
drug
person
medicin
also
appli
field
infecti
diseas
defin
host
predisposit
infect
predict
success
respons
well
advers
reaction
treatment
evid
certain
infecti
diseas
genet
predisposit
initi
came
studi
show
approxim
sixfold
increas
risk
mortal
due
infecti
diseas
adopt
children
biolog
parent
also
die
infect
group
later
confirm
result
sinc
suscept
sever
infecti
diseas
includ
aureu
tuberculosi
link
rare
defect
gene
encod
effector
immun
respons
complet
human
genom
project
map
human
genet
variat
promot
evolut
high
densiti
snp
array
analyz
associ
certain
polymorph
suscept
infecti
diseas
well
linkag
disequilibrium
correl
two
snp
increasingli
common
genomewid
associ
studi
gwa
identifi
seri
gene
implic
predisposit
differ
bacteri
viral
diseas
although
gwa
first
appli
field
rheumat
autoimmun
diseas
approach
recent
identifi
novel
genet
loci
involv
suscept
infecti
diseas
addit
util
gwa
begin
demonstr
identif
marker
indic
qualiti
patient
respons
treatment
exampl
recent
gwa
show
snp
locat
upstream
gene
code
type
iii
interferon
strongli
associ
twofold
differ
respons
antihcv
drug
treatment
studi
show
relationship
gene
polymorph
spontan
clearanc
acut
hcv
sinc
hcv
almost
invari
lead
chronic
diseas
liver
failur
individu
effect
treat
acut
phase
diseas
studi
signific
step
toward
allow
physician
accur
predict
spontan
clearanc
identifi
subgroup
patient
benefit
earli
treatment
microarray
technolog
pave
way
develop
field
transcriptom
largescal
profil
rna
transcript
cell
order
character
gene
express
fig
transcriptom
wide
appli
studi
host
respons
identif
biomark
infect
treatment
case
pattern
gene
express
human
cell
frequent
peripher
blood
mononuclear
cell
pbmc
studi
hybrid
biolog
materi
defin
gene
chip
regard
infecti
diseas
microarray
technolog
made
huge
contribut
understand
chang
evid
transcriptom
human
infect
lempicki
et
al
use
microarrayderiv
gene
express
pattern
demonstr
elev
express
interferonstimul
gene
patient
pbmc
could
one
explan
antihcv
therapi
patient
coinfect
hcv
hiv
lower
success
rate
anoth
studi
jacobsen
et
al
use
microarray
technolog
identifi
biomark
express
infect
tuberculosi
would
allow
accur
predict
regard
outcom
infect
thu
microarray
technolog
broadli
applic
studi
aim
character
infect
profil
varieti
microorgan
includ
sarscov
dengu
influenza
aureu
enterica
advent
nextgener
deep
ultradeep
sequenc
techniqu
also
improv
abil
research
identifi
splice
variant
low
abund
transcriptom
chang
respons
infecti
diseas
data
use
inform
improv
diagnosi
prognosi
diseas
design
antivir
antibiot
therapi
construct
vaccin
specif
target
suscept
popul
applic
new
genom
techniqu
predict
respons
patient
drug
therapi
base
hisher
genet
profil
pharmacogenom
found
practic
applic
identifi
popul
suscept
shortand
longterm
toxic
specif
hiv
antiretrovir
drug
one
exampl
reaction
abacavir
nucleosid
analog
revers
transcriptas
inhibitor
nrti
major
toxic
manifest
hypersensit
reaction
occur
approxim
recipi
within
six
week
commenc
therapi
mallal
et
al
show
patient
carri
allel
like
experi
hypersensit
reaction
abacavir
marker
neg
predict
valu
indic
genet
test
provid
unequivoc
inform
help
predict
prevent
otherwis
unpredict
drug
reaction
anoth
exampl
use
pharmacogenom
guid
therapi
case
antiretrovir
drug
maraviroc
hiv
entri
inhibitor
drug
effect
patient
infect
strain
hiv
use
coreceptor
entri
patient
infect
virus
therefor
screen
specif
tropism
strain
hiv
patient
infect
clinician
specif
target
drug
therapi
exampl
use
maraviroc
patient
infect
suscept
strain
hiv
result
underlin
success
gwa
person
medicin
predict
popul
avoid
treatment
specif
drug
prone
side
effect
although
clinic
applic
omic
system
biolog
hold
great
potenti
medic
discoveri
introduct
highthroughput
technolog
also
introduc
new
question
challeng
regard
transform
larg
volum
data
produc
approach
use
inform
develop
diagnost
prognost
therapeut
devic
larg
n
small
p
paradigm
number
studi
subject
n
higher
variabl
p
gener
studi
current
serv
fundament
analyt
principl
data
model
shift
ratio
toward
smaller
n
valu
compar
larg
number
variabl
amass
highthroughput
data
acquisit
becom
clear
paradigm
need
revis
order
preserv
statist
accuraci
address
problem
research
propos
chang
mathemat
principl
use
data
analysi
use
continu
variabl
nonlinear
model
also
recommend
switch
determinist
probabilitybas
model
strategi
order
account
uncertainti
typic
common
clinic
scenario
predict
rel
probabl
variou
outcom
given
initi
situat
addit
necessari
evolut
data
model
strategi
anoth
critic
factor
success
translat
research
data
capabl
access
analyz
larg
set
data
origin
differ
sourc
contain
divers
type
inform
therefor
need
develop
method
enabl
construct
hybrid
data
set
contain
clinic
biolog
data
organ
way
access
translat
research
compat
among
differ
system
translat
bioinformat
one
emerg
area
propos
offer
holist
approach
issu
provid
integr
method
incorpor
multipl
data
modal
enabl
develop
predict
model
therapeut
respons
although
detail
descript
method
use
data
integr
model
beyond
scope
paper
articl
yan
kanehisa
et
al
sarkar
et
al
offer
complet
review
topic
develop
still
object
research
far
complet
data
keep
accumul
full
develop
new
analyt
strategi
enabl
full
diagnost
clinic
use
mention
advanc
translat
research
applic
infecti
diseas
studi
sever
major
achiev
translat
research
diseas
especi
relev
field
cancer
neurosci
specif
regard
epigenom
stem
cell
research
although
thorough
discuss
field
beyond
scope
paper
impact
translat
research
also
profound
regardless
field
studi
research
techniqu
howev
promis
translat
research
remain
hinder
key
factor
discuss
aforement
studi
illustr
incred
promis
new
technolog
translat
research
full
potenti
remain
larg
untap
part
due
high
failur
rate
long
timelin
cost
convert
basic
scienc
research
clinic
applic
methodolog
recent
propos
ncat
new
nih
entiti
would
includ
ctsa
elimin
ncrr
effort
circumv
roadblock
remaind
review
discuss
time
frame
cost
poor
success
rate
persist
hinder
translat
basic
research
advanc
clinic
use
product
newli
propos
ncat
aim
circumv
roadblock
addit
challeng
face
field
translat
medicin
past
decad
number
nme
approv
us
food
drug
administr
fda
compar
regulatori
bodi
around
world
progress
decreas
second
half
exampl
fda
approv
greater
nme
per
year
contrast
number
nme
approv
sinc
averag
slightli
less
per
year
except
approv
despit
increas
number
potenti
therapeut
compound
identifi
highthroughput
technolog
addit
declin
approv
decreas
number
nme
applic
submit
fda
past
decad
produc
one
lowest
number
year
due
declin
approv
applic
well
increas
use
gener
drug
estim
larg
cap
pharmaceut
compani
abl
replac
averag
cent
everi
dollar
lost
patent
expir
new
product
revenu
accord
current
estim
nme
make
candid
select
preclin
stage
success
launch
declin
drug
develop
threaten
take
econom
toll
medic
one
well
approxim
twoyear
increas
life
expect
attribut
introduct
new
drug
lack
new
drug
especi
worrisom
field
infecti
diseas
emerg
multidrug
resist
pathogen
led
situat
formerli
curabl
infect
untreat
paradox
pharmaceut
compani
indic
curtail
curb
antiinfect
research
major
reason
antiinfect
agent
need
short
time
smaller
popul
make
less
econom
attract
target
drug
target
chronic
diseas
appear
larger
age
popul
eg
antihypertens
antidepress
time
approxim
failur
translat
promis
nme
clinic
applic
occur
earli
clinic
trial
accord
recent
editori
mani
nme
fail
outdat
clinic
trial
design
drug
test
requir
studi
larg
sampl
popul
order
show
statist
signific
benefit
compar
exist
pharmaceut
introduct
specif
marker
person
medicin
make
even
difficult
recruit
patient
qualifi
test
therefor
mani
clinic
trial
take
year
complet
enrol
cancel
due
inabl
recruit
suffici
number
subject
failur
therefor
contribut
total
cost
failur
rate
translat
research
result
mani
nme
never
develop
compani
remov
product
pipelin
ever
circumv
problem
increas
success
rate
propos
nme
franci
collin
propos
sever
prioriti
new
ncat
first
ncat
support
studi
investig
broadli
applic
rather
diseasespecif
target
valid
approach
ie
target
may
relev
multipl
diseas
well
target
consid
riski
industri
invest
identifi
gwa
second
ncat
encourag
use
omic
system
biolog
approach
order
help
design
valid
new
diagnost
therapeut
translat
clinic
applic
third
ncat
would
also
hous
recent
establish
nihfda
regulatori
scienc
initi
launch
goal
facilit
improv
regulatori
scienc
provid
new
insight
broadli
benefit
field
translat
research
final
togeth
nihepafda
consortium
ncat
would
support
use
new
cellbas
approach
mean
pursu
preclin
toxicolog
studi
current
estim
averag
timelin
discov
develop
nme
approxim
year
estim
includ
regulatori
review
time
take
identifi
valid
target
pathway
time
spent
clinic
trial
unnecessari
bureaucrat
procedur
associ
research
design
manag
ineffici
regulatori
review
identifi
contributor
problem
minim
problem
propos
ncat
would
seek
encourag
reengin
translat
process
initi
target
identif
firstinhuman
applic
small
molecul
biolog
diagnost
devic
order
streamlin
process
attract
pharmaceut
involv
addit
center
would
aim
act
honest
broker
hasten
institut
review
board
irb
approv
multicent
trial
decreas
time
nme
spend
clinic
trial
facilit
rescu
repurpos
abandon
compound
lastli
center
would
support
collabor
effort
test
new
entiti
act
proof
concept
hope
promis
new
drug
would
pick
industri
cost
translat
endeavor
inexor
link
high
failur
rate
long
timelin
inde
averag
cost
bring
nme
market
estim
billion
dollar
estim
appear
regardless
whether
nme
produc
big
pharmaceut
compani
small
biotechnolog
firm
ncat
would
aim
decreas
cost
number
way
first
would
encourag
use
earli
human
trial
also
call
phase
zero
clinic
trial
microdos
new
drug
administ
small
number
patient
trial
absorpt
tissu
distribut
toxic
drug
assess
highli
sensit
methodolog
molecular
imag
metabolom
proteom
feasibl
endeavor
alreadi
demonstr
consortium
metabonom
toxicolog
imperi
colleg
london
show
possibl
design
predict
model
clinic
toxic
use
metabolom
data
anoth
way
ncat
would
decreas
develop
cost
encourag
innov
model
includ
human
tissu
biobank
stem
cell
model
tissueengin
organoid
model
would
potenti
allow
research
decreas
omit
use
anim
model
critic
costli
accur
predict
efficaci
human
final
ncat
would
encourag
develop
technolog
aim
biomark
identif
alreadi
use
research
design
new
style
adapt
clinic
trial
studi
design
chang
new
data
collect
allow
patient
like
respond
assign
treatment
given
compound
beyond
encourag
develop
new
technolog
aim
decreas
cost
ncat
would
promot
crosscollabor
academ
institut
biotechnolog
firm
philanthrop
organ
pharmaceut
compani
order
split
research
develop
cost
lastli
propos
cure
acceler
network
assess
congression
fund
next
fiscal
year
would
provid
nih
abil
award
billion
dollar
per
year
academ
privat
consortia
direct
develop
certain
especi
promis
therapeut
need
encourag
develop
new
drug
therapeut
clear
express
concern
propos
ncat
repres
chang
prioriti
nih
away
basic
discoverybas
scienc
toward
applicationfocus
research
thu
neglect
fact
basic
scienc
lay
foundat
translat
research
inde
critic
sinc
develop
ctsa
anoth
critic
support
gwa
highthroughput
methodolog
caus
dramat
shift
research
hypothesisbas
datadriven
place
overemphasi
screen
drug
biomark
expens
discoverybas
scienc
exampl
studi
base
highthroughput
technolog
typic
result
experi
design
test
hypothesi
rather
aim
systemat
identifi
molecular
effector
involv
specif
system
comprehens
effici
way
possibl
order
address
critiqu
author
ad
extra
step
complex
highthroughput
method
determin
mechanist
function
molecul
identifi
switch
way
fish
expedit
discoverybas
research
end
despit
assert
establish
ncat
reinforc
rather
detract
basic
scienc
mani
investig
continu
concern
mostli
relat
money
today
climat
fund
cut
wonder
possibl
receiv
fund
basic
ie
less
obvious
applic
research
emphasi
collabor
multidisciplinari
approach
shift
major
fund
toward
multicent
group
establish
scientist
make
difficult
new
investig
surviv
current
emphasi
clinic
applic
result
narrow
idea
perspect
result
major
fund
alloc
wellestablish
scientist
pursu
tradit
approach
beyond
concern
regard
chang
focu
nih
exist
concern
regard
polici
infrastructur
whether
fund
ncat
program
take
money
away
program
previous
hous
within
ncrr
ncrr
current
award
fund
approxim
billion
dollar
annual
substanti
concern
none
ncrr
program
current
slate
discontinu
perceiv
lack
transpar
surround
establish
ncat
dissolut
ncrr
program
formerli
hous
within
ncrr
locat
result
persist
scrutini
nih
stakehold
congress
perhap
greatest
issu
debat
draw
line
public
privat
industri
mani
critic
propos
ncat
believ
design
help
compani
develop
new
drug
decreas
financi
risk
use
taxpay
money
also
argu
nih
experi
basic
scienc
research
drug
develop
inde
argu
declin
research
develop
product
relat
increas
cost
sinc
public
invest
pharmaceut
industri
increas
proport
sinc
due
time
attrit
rate
steadi
sinc
instead
argu
may
due
poor
priorit
mismanag
within
pharmaceut
industri
specif
chang
manag
techniqu
pharmaceut
industri
hierarchi
led
corpor
polici
discourag
innov
favor
costcut
risk
minim
togeth
shift
control
scientist
research
market
focu
shortterm
profit
fast
sale
growth
discontinu
compound
nontechn
reason
led
decreas
translat
scientif
discoveri
clinic
applic
argu
develop
ncat
may
make
even
less
like
pharmaceut
industri
tri
solv
problem
ultim
though
ncat
may
serv
champion
key
therapeut
compound
pharmaceut
industri
need
reform
certain
practic
pace
drug
develop
keep
pace
translat
research
translat
research
made
incred
progress
recent
year
develop
new
techniqu
expans
holist
way
view
data
stem
approach
part
discoveri
novel
technolog
develop
new
infrastructur
train
bud
scientist
support
evolut
transit
complet
roadblock
still
exist
path
scientif
progress
remain
seen
whether
newli
propos
ncat
rais
mani
object
hope
answer
problem
evid
howev
translat
research
must
repriorit
bolster
way
increas
speed
promis
drug
technolog
move
pipelin
clinic
applic
time
refrain
stifl
breadth
idea
creativ
basic
research
necessari
progress
scienc
topdown
explan
omic
genom
studi
complet
set
hereditari
genet
inform
organ
advent
microarray
technolog
nextgener
sequenc
numer
applic
arisen
field
genom
includ
pathogen
discoveri
epidemiolog
advanc
varieti
molecular
techniqu
allow
precis
manipul
microbi
genom
dna
beget
rna
protein
field
transcriptom
proteom
follow
logic
genom
transcriptom
subset
field
genom
concern
collect
mrna
transcript
express
within
organ
emerg
result
sophist
techniqu
allow
highli
sensit
determin
lowabund
mutat
transcript
snp
proteom
next
major
omic
field
genom
focus
complement
protein
modif
interact
within
organ
aid
analyt
techniqu
msm
shotgun
proteom
field
proteom
found
use
applic
identif
biomark
map
epitop
may
provid
target
antimicrobi
drug
develop
field
metabolom
natur
offshoot
proteom
use
mani
ms
techniqu
major
differ
howev
genom
proteom
provid
insight
potenti
cellular
process
metabolom
give
instantan
snapshot
actual
happen
cell
one
omic
field
gener
massiv
amount
rich
detail
data
surpass
capabl
manual
data
analysi
therefor
necessit
incorpor
bioinformat
develop
comput
algorithm
use
analyz
model
data
omic
paradigm
hostmicrob
interact
stateoftheart
omic
technolog
pave
way
comprehens
character
varieti
host
microb
microbiom
virom
mycobiom
three
microorganismspecif
data
set
arisen
omic
revolut
although
subset
compris
distinct
inform
target
bacteria
virus
fungi
etc
exist
isol
increas
number
studi
focus
intersect
collect
set
microbi
omic
profil
gene
express
associ
human
diseas
diseasom
thu
investig
complex
dynam
occur
infect
infectom
provid
signific
insight
regard
etiolog
progress
diseas
well
lead
identif
target
aim
therapeut
intervent
